- DEM301 is a first-in-class bifunctional antibody drug conjugate (ADC) targeting a novel plasma membrane protein overexpressed in colorectal cancer and other gastrointestinal malignancies - - Pre-IND ...

NVIDIA and Intel had their moment in the spotlight, and now it's AMD's turn. The chipmaker is kicking off CES 2026 on Monday night, where it'll cover its latest AI developments and perhaps show off ...

Last year during CES 2025, NVIDIA spent most of the time during its keynote touting its leading position in artificial intelligence. It threw in a few hardware announcements, including its RTX ...

RALEIGH, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences ...

MIAMI, FLORIDA (Nov. 13, 2025) – Below are titles – linked to more than 100 poster abstracts – that will be presented at ASH 2025 involving researchers from Sylvester Comprehensive Cancer Center and ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...

What’s happened? If you dread building slide decks, Google just made it a cakewalk to turn your files or ideas into a presentation. In its latest update, Gemini’s Canvas can now generate complete ...

MILAN (AP) — The Milan-Cortina 2026 Olympic organizing committee on Wednesday unveiled two official posters for the Winter Olympic and Paralympic Games — bold graphic depictions that officials said ...

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...

SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class WEE1 inhibitor for ...